#### 1 Distinct T cell functional profiles in SARS-CoV-2 seropositive and seronegative children

- 2 associated with endemic human coronavirus cross-reactivity.
- 3
- Ntombi S. B. Benede<sup>1,2</sup>, Marius B. Tincho<sup>1,2</sup>, Avril Walters<sup>1,2</sup>, Vennesa Subbiah<sup>1,2</sup>, Amkele 4
- Ngomti<sup>1,2</sup>, Richard Baguma<sup>1,2</sup>, Claire Butters<sup>1</sup>, Mathilda Mennen<sup>3</sup>, Sango Skelem<sup>3</sup>, 5
- Marguerite Adriaanse<sup>3</sup>, Strauss van Graan<sup>4,5</sup>, Sashkia R. Balla<sup>4,5</sup>, Thandeka Moyo-Gwete<sup>4,5</sup>, 6
- Penny L. Moore<sup>1,4,5,6</sup>, Maresa Botha<sup>7,8</sup>, Lesley Workman<sup>7,8</sup>, Heather J. Zar<sup>1,7,8,9</sup>, Ntobeko A. 7
- B. Ntusi<sup>1,3,9,10</sup>, Liesl Zühlke<sup>1,7,10,11</sup>, Kate Webb<sup>11,12</sup>, Catherine Riou<sup>1,2,9</sup>, Wendy A. Burgers<sup>1,2,9</sup>, Roanne S. Keeton<sup>1,2\*</sup> 8
- 9
- 10
- <sup>1</sup>Institute of Infectious Disease and Molecular Medicine, University of Cape Town, 11
- **Observatory**, South Africa 12
- <sup>2</sup>Division of Medical Virology, Department of Pathology, University of Cape Town, 13
- Observatory, South Africa 14
- <sup>3</sup>Department of Medicine, University of Cape Town and Groote Schuur Hospital, 15
- Observatory, South Africa 16
- <sup>4</sup>National Institute for Communicable Diseases of the National Health Laboratory Services, 17
- 18 Johannesburg, South Africa;
- <sup>5</sup>MRC Antibody Immunity Research Unit, School of Pathology, University of the 19
- Witwatersrand, Johannesburg, South Africa; 20
- <sup>6</sup>Centre for the AIDS Programme of Research in South Africa, Durban, South Africa; 21
- <sup>7</sup>Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South 22
- Africa. 23
- <sup>8</sup>Medical Research Council (MRC) Unit on Child and Adolescent Health, University of Cape 24
- Town, Cape Town, South Africa 25
- <sup>9</sup>Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, 26
- 27 Observatory, South Africa
- <sup>10</sup>Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Observatory, 28
- 29 South Africa.
- <sup>11</sup>South African Medical Research Council, Francie Van Zijl Drive, Parow Cape Town, South 30 31 Africa
- <sup>12</sup>Crick African Network, The Francis Crick Institute, London, United Kingdom. 32
- <sup>13</sup>Division of Paediatric Rheumatology, Department of Paediatrics and Child Health, Red 33
- Cross War Memorial Children's Hospital, University of Cape Town, Observatory, South 34
- 35 Africa
- 36
- 37
- \*Correspondence: Roanne S. Keeton (roanne.keeton@uct.ac.za) 38
- 39

### 40 **SUMMARY** (Word count: 148/150)

41 SARS-CoV-2 infection in children typically results in asymptomatic or mild disease. There is

- 42 a paucity of studies on antiviral immunity in African children. We investigated SARS-CoV-
- 43 2-specific T cell responses in 71 unvaccinated asymptomatic South African children who
- 44 were seropositive or seronegative for SARS-CoV-2. SARS-CoV-2-specific CD4+ T cell
- 45 responses were detectable in 83% of seropositive and 60% of seronegative children.
- 46 Although the magnitude of the CD4+ T cell response did not differ significantly between the
- 47 two groups, their functional profiles were distinct, with SARS-CoV-2 seropositive children
- 48 exhibiting a higher proportion of polyfunctional T cells compared to their seronegative
- 49 counterparts. The frequency of SARS-CoV-2-specific CD4+ T cells in seronegative children
- 50 was associated with the endemic human coronavirus (HCoV) HKU1 IgG response. Overall,
- 51 the presence of SARS-CoV-2-responding T cells in seronegative children may result from
- 52 cross-reactivity to endemic coronaviruses and could contribute to the relative protection from
- 53 disease observed in SARS-CoV-2-infected children.
- 54
- Key words: SARS-CoV-2, Children, IgG responses, T cell response, Polyfunctional profile,
   endemic HCoV

57

# 58 INTRODUCTION:

59 Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection in children

60 usually causes asymptomatic or mild illness, contrasting with the high rate of severe disease

61 reported in older adults <sup>1,2</sup>. As a result, global reports of coronavirus disease 2019 (COVID-

62 19) cases among children and adolescents are underreported. The United Nations

63 International Children's Emergency Fund (UNICEF) estimates that 21% of all reported

64 confirmed cases occur in individuals younger than 20 years <sup>3</sup>.

In the USA, it has been documented that COVID-19-associated hospitalization rates among

children less than 18 years were lower compared to those in older individuals<sup>4</sup>. Indeed, the

67 COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) reported that

children younger than 18 years accounted for only 4.2% of COVID-19-associated

69 hospitalization and 0.2% of COVID-19-associated in-hospital deaths <sup>5</sup>. In South Africa,

during the first 2 years of the pandemic, 12.5% of confirmed cases and 0.7% of COVID-19

associated in-hospital deaths were in individuals younger than 19 years  $^{6}$ .

72 In contrast to the low COVID-19 severity in the majority of younger individuals, it is known

that children are more susceptible than adults to other acute viral respiratory tract infections

<sup>74</sup> including respiratory syncytial virus (RSV), rhinovirus (RV), influenza virus and common

r5 circulating human coronaviruses (HCoV)<sup>7</sup>. Several age-associated factors have been

proposed to play a role in the reduction of severity to SARS-CoV-2 infection in children  $^{2,8}$ ,

<sup>77</sup> including limited comorbidities <sup>9–11</sup>, differences in the expression of SARS-CoV-2 viral

entry factors 12-14, robust innate immune responses 15-18, humoral and cellular immunity 19-21

and pre-existing immunity against common cold circulating endemic HCoVs  $^{22-26}$ . Endemic

HCoVs account for 15 to 30% of respiratory infections reported annually in children  $^{27,28}$ .

81 These HCoVs belong to the alpha-coronavirus subfamily (HCoV-229E and HCoV-NL63)

and the beta-coronavirus subfamily (HCoV-OC43 and HCoV-HKU1) and have seasonal

infection peaks during the winter season and are responsible for high rates of infection among 2930

84 children  $^{29,30}$ .

85 It is well established that protective immune responses to SARS-CoV-2 encompass both an

antibody as and T cell components  $^{31}$ . Several studies have reported robust and durable

antibody and T cell responses against SARS-CoV-2, which are maintained up to 6-12 months

following infection  $^{21,32-35}$ . However, data on T cell responses in children compared to adults

are conflicting, with studies reporting lower SARS-CoV-2-specific T cell responses in

- 90 children  $^{23,36,37}$ , no differences  $^{38}$  or greater T cell responses in children  $^{22}$ . Many of these
- studies make use of ELISPOT assays which preclude analysis of T cell phenotypes or
- 92 functional cytokine profiles.
- 93 In this study, we prospectively characterized specific T cell responses in SARS-CoV-2
- seropositive and seronegative children during the COVID pandemic and determined the
- 95 functional profiles of SARS-CoV-2-specific T cells, in the context of their pre-existing
- 96 immunity against endemic beta-HCoVs. This study provides novel insights into cross-
- 97 reactive immunity to SARS-CoV-2 in children.

#### 98 **RESULTS**:

#### 99 Study cohort

- 100 To investigate SARS-CoV-2-specific immune responses, we measured immunoglobulin (Ig)
- 101 G and T cell responses in 71 children recruited in Cape Town, Western Cape, South Africa.
- 102 The participants are described in Figure 1A. The median age of the children was 7 years
- 103 (interquartile range (IQR) 2.8-9 years) and 34% (24/71) were female. The children included
- 104 in this study had not received any SARS-CoV-2 vaccine prior to recruitment and no PCR-
- 105 confirmed infection data were available, although 58% showed SARS-CoV-2 seropositivity
- 106 (defined as being positive for either anti-spike or anti-nucleocapsid IgG). Samples were
- 107 collected between 1 February 2021 20 May 2021, after two infection waves in South
- 108 Africa, that were dominated by the ancestral D614G strain followed by the Beta variant of
- 109 concern  $^{39}$ .

### 110 SARS-CoV-2-specific antibody responses in children

- 111 To characterize the children serologically, we measured IgG responses against SARS-CoV-2
- spike (S) and nucleocapsid (N) proteins using an indirect Enzyme-linked immunosorbent
- assay (ELISA) (Figure 1B). A large proportion (58%, 41/71) of unvaccinated children had
- 114 detectable SARS-CoV-2-specific IgG against spike and/or nucleocapsid proteins and were
- classified as seropositive. Of the seropositive children, 30% (21/71) had spike- and
- nucleocapsid-specific IgG, 23% (16/71) had only spike-specific IgG and 5% (4/71) had only
- 117 nucleocapsid-specific IgG only (Figure 1B).-The remaining 42% (30/71) had undetectable
- 118 SARS-CoV-2-spike and nucleocapsid-specific IgG and were classified as seronegative
- 119 (Figure 1B). IgG responses to spike and nucleocapsid are shown for the 41 seropositive
- 120 children in **Figure 1C**.

#### 121 SARS-CoV-2-specific T cell responses in children

- 122 The magnitude of SARS-CoV-2-specific T cell responses in children was quantified using a
- 123 whole blood assay and intracellular cytokine staining followed by flow cytometry. SARS-
- 124 CoV-2-specific CD4+ and CD8+ T cell responses were measured as total cytokine
- 125 production of interferon- $\gamma$  (IFN- $\gamma$ ), tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) or interleukin-2 (IL-2) in
- 126 response to a combined peptide pool covering SARS-CoV-2 spike (S), nucleocapsid (N) and
- 127 membrane (M) proteins (Figure 2A).

128 We assessed the proportion of responders and magnitude of SARS-CoV-2-specific T cell 129 responses according to the serostatus of the children (Figure 2B and C). As expected, 83% 130 (34/41) of seropositive children had detectable SARS-CoV-2-specific CD4+ T cells. 131 Interestingly, 60% (18/30) of seronegative children also had detectable SARS-CoV-2-specific 132 CD4+ T cells, although this was a significantly lower proportion than observed in the 133 seropositive group (p=0.0311). The magnitude of the SARS-CoV-2-specific CD4+ T cell 134 response in seronegative responders was comparable to that observed in seropositive children 135 (median of responders: 0.04% and 0.057% respectively; p=0.437, Figure 2B). Conversely, 136 we did not observe significant differences in the proportion of SARS-CoV-2 CD8+ T cell 137 responders (~50%) or the frequency of SARS-CoV-2-specific CD8+ T cells between 138 seropositive and seronegative children (median of responders: 0.019% and 0.025% 139 respectively; p=0.214, Figure 2C). 140 Next, we evaluated the polyfunctional profile of SARS-CoV-2-responding CD4+ and CD8+ 141 T cells based on the co-expression of IFN- $\gamma$ , IL-2 or TNF- $\alpha$  (Figure 2D, E). The overall 142 functional profile of SARS-CoV-2-specific CD4+ T cells in seropositive children was distinct 143 from that of seronegative children (p=0.007, Figure 2D). SARS-CoV-2-specific CD4+ T 144 cells in seropositive children were more polyfunctional, exhibiting a higher proportion of 145 triple functional IFN- $\gamma$ +IL-2+TNF- $\alpha$ +-producing CD4+ T cells (p=0.0044), and dual 146 expressing cells (IL-2+TNF- $\alpha$ +, p=0.0048; IFN- $\gamma$ +IL-2+, p $\leq$ 0.0001) compared to the 147 seronegative children. In contrast, seronegative children were characterized by an increased 148 proportion of IFN- $\gamma$  monofunctional CD4+ T cells (p=0.0048). Considering the CD8 149 compartment, we detected no significant differences in the overall functional profile of 150 SARS-CoV-2-responding CD8+ T cells between the two groups (p=0.098), although 151 seropositive children did have a larger proportion of CD8+ T cells producing both IFN- $\gamma$  and

152 IL-2 (p=0.027) and single IFN- $\gamma$  (p=0.011) (**Figure 2E**).

153 Taken together, these data show that a significant proportion of seronegative children have

detectable SARS-CoV-2-specific CD4+ and CD8+ T cells. Notably, these CD4+ T cells

exhibit a distinct polyfunctional profile compared to those found in SARS-CoV-2-exposed

156 children.

# 157 Pre-existing immunity to endemic common circulating human coronaviruses

- 158 The presence of SARS-CoV-2-responding CD4+ T cells primarily exhibiting a
- 159 monofunctional profile observed in seronegative children led us to hypothesize that the T cell

160 response could be due to cross-reactivity resulting from prior infection with common

161 circulating endemic HCoVs. Therefore, we measured endemic betacoronavirus HCoV-HKU1

- and HCoV-OC43 spike IgG in SARS-CoV-2 seropositive and seronegative children. The
- 163 magnitude of both HCoV-HKU1 (Figure 3A) and HCoV-OC43 (Supplemental Figure 1A)
- spike IgG was comparable in the seropositive and seronegative groups (median OD: 0.746 vs
- 165 0.420; p=0.153 for HCoV-HKU1 and 1.769 vs 1.281; p=0.07 for HCoV-OC43, respectively).
- 166 We found a significant correlation between the frequency of SARS-CoV-2-specific CD4+ T
- 167 cells and HCoV-HKU1-spike IgG in seronegative children (p=0.036, r=0.392, Figure 3B),
- while no correlation was observed in seropositive children (p=0.936, r=-0.013, **Figure 3C**).
- 169 For HCoV-OC43, no correlation was detected in either the seronegative (p=0.324, r=-0.187,
- **Supplemental Figure 1B**) or the seropositive group (p=0.171, r=-0.218, **Supplemental**

171 Figure 1C). Overall, these results indicate SARS-CoV-2-reactive CD4+ T cell responses in

- seronegative children could be due in part to cross-reactive T cell immunity resulting from
- 173 prior infection with common cold HCoV-HKU1.

174

# SARS-CoV-2-specific T cell responses in SARS-CoV-2 seropositive children compared to COVID-19 convalescent adults

177 Blood and plasma samples were collected from 30 COVID-19 convalescent healthcare

178 workers (HCWs) participating in a longitudinal study at Groote Schuur Hospital (Cape Town,

179 Western Cape, South Africa) (Figure 4A). All convalescent adults had a prior PCR-

180 confirmed SARS-CoV-2 infection (median 224 days prior to sampling) and had not received

a COVID-19 vaccine at the time of sampling. Samples were collected between 22 January

182 2021 – 23 February 2021.

183 A trend towards a higher proportion of SARS-CoV-2 CD4 responders was observed in

184 convalescent adults (97%) compared to seropositive children (83%) (p=0.07, Figure 4B).

185 Moreover, in SARS-CoV-2 responders, convalescent adults did have a significantly higher

186 frequency of SARS-CoV-2-specific CD4+ T cells compared to seropositive children (median

187 of responders: 0.092% vs 0.057%; p=0.0004, respectively). Unlike CD4+ T cell responses,

- there were no significant differences in either the proportion of CD8 responders (53% vs
- 189 49%, p=0.705) or the frequency of SARS-CoV-2-specific CD8+ T cells (median of
- responders: 0.038% vs 0.019%; p=0.096) between convalescent HCWs and seropositive
- 191 children (**Figure 4C**). Furthermore, we observed a positive correlation between age and the

- 192 frequency of SARS-CoV-2-specific CD4+ T cells (p=0.0006, r=0.396, Figure 4D). No
- 193 correlation was observed with SARS-CoV-2-specific CD8+ T cells and age (p=0.116,
- 194 r=0.188, Figure 4E). Overall, these results show that convalescent adults mount higher
- 195 SARS-CoV-2-specific CD4 T cell responses compared to children, which could be attributed
- 196 to age-related T cell development.

#### 197 **DISCUSSION**

T cells have been associated with protection from severe COVID-19  $^{40}$ . It is therefore 198 important to understand the nature of T cell responses targeting SARS-CoV-2 in children, 199 who have been largely spared from severe COVID-19. In this study, comparing SARS-CoV-200 201 2-specific T cell responses in SARS-CoV-2 seropositive and seronegative children, a sizable 202 proportion of seronegative children had SARS-CoV-2-reactive CD4+ and CD8+ T cells, but 203 their CD4+ T cells exhibited a distinct functional profile compared to seropositive children. 204 Importantly, in seronegative children, the frequency of SARS-CoV-2-reactive CD4+ T cells 205 positively associated with HCoV-HKU1 spike-specific IgG antibodies. Additionally, we 206 showed that convalescent adults had a higher magnitude of CD4+ T cell responses against 207 SARS-CoV-2 compared to seropositive children, which associated positively with age. 208 Our data are in accordance with several studies showing that children develop robust humoral and cellular immunity to SARS-CoV-2<sup>20,22,38,41,42</sup>. In addition, SARS-CoV-2-specific T cell 209 210 responses have been detected in 40-60% of SARS-CoV-2 unexposed individuals including children and adults <sup>22,23,43-48</sup> suggesting possible cross reactivity to HCoVs. One study 211 demonstrated that the proportion of T cell responders was higher in children than adults  $^{22}$ . In 212 213 contrast, a study by Tsang et al. found that SARS-CoV-2 uninfected children failed to mount detectable T cell responses <sup>41</sup>. A further study showed that only a small proportion of 214 215 seronegative children mounted a SARS-CoV-2-specific CD4+ T cell response (13%) compared to 60% in seropositive siblings, despite similar exposure in shared households <sup>42</sup>. 216

These two studies differ from our findings, where we showed that 60% of seronegative

218 children had detectable SARS-CoV-2-specific T cell responses, consistent with Dowell et al

<sup>219</sup>. The discrepancies between the studies could be due to a difference in the seasonal

prevalence of circulating HCoVs in each study setting <sup>29,30,49</sup>, different T cell assays used to

analyze T cell responses, and/or the cohort demographics.

Although the source of SARS-CoV-2 reactive T cells in seronegative children remains

223 unclear, mounting evidence argues for cross-reactivity to endemic HCoVs. HCoVs (including

beta HCoVs-HKU1 and OC43, and alpha HCoVs-NL63 and 229E) have partial sequence

homology with SARS-CoV-2  $^{44,50}$ . While cross reactive humoral responses have been shown

not to underly this protection <sup>51</sup>, studies have reported pre-existing T cell responses to

endemic HCoVs with cross-reactivity to SARS-CoV-2 in unexposed adults <sup>47,52–57</sup> and

children <sup>22,24,58,59</sup>. These cellular responses were targeted mainly towards the S2 subunit

9

which is highly conserved among coronaviruses <sup>22,25</sup>. In our study, we showed a positive
correlation between the frequency of SARS-CoV-2 CD4+ T cells and the magnitude of
HKU1 spike-specific IgG in SARS-CoV-2 seronegative children. Our findings are supported
by similar findings showing that 58% (7/12) seronegative children had binding antibodies
against alpha and/or beta HCoV spike proteins, which they concluded were likely due to
recent HCoV infection <sup>22</sup>.

235 Pre-existing immunity from endemic HCoVs infection or exposure has been shown to be

associated with a protective effect against COVID-19 disease in adults <sup>53,56,57,60,61</sup>. Sagar et al.

showed that individuals with a documented recent or ongoing HCoV infection and SARS-

238 CoV-2 infection had fewer COVID-19-associated complications when hospitalized,

compared to individuals without HCoV infection <sup>60</sup>. Previously, the clinical relevance of pre-

existing immunity and cross-reactive cellular responses in providing protection from

241 infection in children was unclear. Recently however, Dowell et al. demonstrated that as for

242 SARS-CoV-2 seropositive children, SARS-CoV-2-reactive T cell responses in SARS-CoV-2

243 seronegative children were protective against Omicron infection, suggesting a protective role

in SARS-CoV-2 unexposed individuals  $^{62}$ .

245 Polyfunctional T cells have been reported to be associated with protection against a number

of viral diseases <sup>63–66</sup>. These include protection against cytomegalovirus (CMV) infection

247 after lung transplantation <sup>64</sup>, improved viral control of hepatitis C virus (HCV) <sup>65</sup> and

248 detection during human immunodeficiency virus (HIV) infection in long term non-

249 progressors <sup>66</sup>. We found that seropositive children had a more polyfunctional profile of

250 SARS-CoV-2-specific CD4+ T cells while CD4 responses in seronegative children exhibited

a predominantly monofunctional profile. The SARS-CoV-2-specific polyfunctional Th1 CD4

response (characterized by co-expression of IFN- $\gamma$ , TNF- $\alpha$  and/or IL-2), as seen in

seropositive children, may be necessary for effective viral control and has been documented

in COVID-19 convalescent adults  $^{67,68}$ .

255 The distinct functional profiles reported in our findings could be a result of differing degrees

256 memory cell T cell differentiation or low SARS-CoV-2 peptide binding affinity with HCoV-

specific T cells resulting in low T cell activation. The affinity between MHC molecules

258 presenting peptide and the T cell receptor (TCR) plays a role in antigen recognition. It has

259 been proposed that T cells with high affinity TCRs have greater effector functions and

therefore an increased polyfunctional profile compared to low affinity TCRs<sup>69,70</sup>. TCR cross-

261 recognition of peptides on MHCs that are not structurally identical results in lower binding affinity which decreases T cell polyfunctionality <sup>70,71</sup>. It is therefore plausible that the 262 monofunctional profile of SARS-CoV-2 CD4+ T cell responses in seronegative children 263 264 observed in our study may be mediated by cross-recognition of pre-existing T cell immunity 265 to HCoV-HKU1, where partial sequence homology between HCoV-HKU1 and SARS-CoV-2 results in low peptide binding affinity and a different functional T cell profile <sup>44,55,69,71,72</sup>. It is 266 267 noteworthy to report that we did not find any association with the other beta HCoV-OC43 268 spike-specific IgG and SARS-CoV-2-specific T cells in seronegative children, which could 269 be related to differences in seasonal prevalence of types of HCoV infections. 270 Numerous studies have now compared the magnitude of the SARS-CoV-2 specific T cell response in children to those detectable in adults <sup>22,23,36–38,41</sup>. Initially it was thought that 271 children may have a higher magnitude of T cell responses given their relative resistance to 272 severe disease and the link between T cell responses and protection from severe disease<sup>8,73</sup>. 273 274 However, children were shown to have lower T cell responses than adults in most studies, including the current study <sup>23,36,37</sup>. A plausible explanation is that adults have a mature 275 276 immune system with more differentiated memory T cell subsets endowed with increased 277 cytokine capacity, whereas children have an immature immune system, with many more 278 naïve T cells which have reduced cytokine producing capacity, are enriched for monofunctional responses and have increased antigen dependence <sup>74</sup>. Despite lower 279 280 circulating SARS-CoV-2-specific T cells, children and adults may also have different 281 responses in the respiratory tract. There is evidence in adults demonstrating the presence of 282 SARS-CoV-2-specific T cell responses in the nasal mucosa after infection and vaccination <sup>75,76</sup>. However comparative studies have yet to be performed in children. Additionally, several 283 284 studies have proposed that one potential contributing factor to age-related COVID-19 clinical 285 outcome are the robust innate immune responses observed in children, which may contribute to early control of viral replication  $^{15-17,77}$ . Recent studies have shown that, compared to 286 287 adults, SARS-CoV-2 seronegative children exhibited an increased number of innate immune 288 cells with pre-activated signatures leading to early production of interferon-mediated antiviral 289 effects in the upper respiratory tract <sup>18,19</sup>.

290 In conclusion, our study shows that a robust SARS-CoV-2-specific T cell response is

observed in children, including in those with no evidence of prior SARS-CoV-2 infection.

292 We demonstrate that the magnitude of SARS-CoV-2-reactive CD4+ T cells in seronegative

293 children correlates with HCoV-HKU1 exposure. This, together with a distinct functional

294 1	profile of SARS-CoV	2-specific responding	CD4+ T cells observed between	seropositive and
2J7		2-specific responding		scropositive and

- seronegative children provides further evidence for pre-existing T cell responses cross-
- 296 reactive to SARS-CoV-2.

### 297 Limitations of the study

- 298 This study relied on serology to determine SARS-CoV-2 exposure. With no PCR
- 299 confirmation of SARS-CoV-2 infection, the exact time of infection of the children could not
- be determined. Additionally, our study investigated T cell responses against SARS-CoV-2
- 301 spike, nucleocapsid and membrane proteins, and not the non-structural viral proteins that can
- 302 also serve as targets for the T cell response, thus not capturing the full extent of T cell
- reactivity in infected participants. Furthermore, we did not address durability of the T cell
- responses in children due to the cross-sectional design of the study.
- 305
- 306
- 307
- 308
- 309
- 310
- 311
- 312

313

- 314
- 315
- 316
- 317

### 318 **DMETHODS**:

#### 319 Lead contact

- 320 Further information and requests for resources and reagents should be directed to and will be
- fulfilled by the lead contact: Roanne S. Keeton (<u>roanne.keeton@uct.ac.za</u>).

322

#### 323 Materials availability

324 Materials will be made available by request to Roanne S. Keeton (<u>roanne.keeton@uct.ac.za</u>).

325

# 326 Data and code availability

- 327 The published article includes all data generated or analyzed during this study, and
- summarized in the accompanying tables, figures, and supplemental materials.

329

# 330 EXPERIMENTAL MODEL AND SUBJECT DETAILS

#### 331 Study participants

332 Paediatric participants (n=71) were recruited from two cohorts in the Western Cape, South

Africa. The first cohort enrolled 50 children from the Red Cross War Memorial Children's

Hospital (Cape Town, Western Cape, South Africa). In this cohort 50/71 children were

- hospitalized for non-COVID-19-related elective procedures. A further 21 children were
- enrolled from the Drakenstein Child Health Study (DCHS) (Cape Winelands Western Cape,
- South Africa), a birth cohort study  $^{78}$ . The participants from this study were recruited between
- 1 February 2021 and 20 May 2021, after the first and the second infection waves with
- Ancestral strain and Beta variant in South Africa <sup>79</sup>. Parents or legal guardians provided
- 340 written informed consent for all paediatric participants. For the DCHS longitudinal cohort,
- this was renewed annually. The study was approved by the University of Cape Town Human
- 342 Research Ethics Committee (HREC 599/2020 for the RC cohort and HREC 401/2009 for the
- 343 DCHS cohort).
- 344 COVID-19 convalescent unvaccinated adults from a longitudinal study of healthcare workers
- 345 (HCW) enrolled from Groote Schuur Hospital (Cape Town, Western Cape, South Africa)

were included in the study (n=30). HCW in this cohort were recruited between July 2020 and

January 2021 and were selected for inclusion based on a prior PCR-confirmed SARS-CoV-2

348 infection at least 3 months earlier. All participants were asymptomatic or had mild symptoms

and did not require hospitalization for COVID-19 and were symptom-free at the time of

sampling. Written informed consent was obtained from all participants and the study was

approved by the University of Cape Town Human Research Ethics Committee (HREC

352 190/2020 and 209/2020).

353

# 354 METHODS DETAILS

### 355 SARS-CoV-2 and HCoV antigens

356 For serology assays, recombinant SARS-CoV-2 spike S1 (Cape Bio Pharms), and SARS-

357 CoV-2 nucleocapsid (BioTech Africa) proteins were used for this study.

358 HKU1 and OC43 spike proteins were expressed in Human Embryonic Kidney (HEK) 293F

359 suspension cells by transfecting the cells with the spike plasmid. After 6 days, proteins were

purified using a nickel resin followed by size-exclusion chromatography. Relevant fractions
were collected and frozen at -80°C until use.

362 SARS-CoV-2 peptides used for T cell assays included a commercially available peptide pool
 363 (15mers peptides with 11 amino acid overlap) covering the immunodominant regions of

364 SARS-CoV-2 spike protein (PepTivator SARS-CoV-2 Prot\_S, Miltenyi Biotech) based on

the Wuhan-1 strain. The Spike peptide pool was prepared by resuspending in distilled water

and used at a final concentration of 1  $\mu$ g/ml. SARS-CoV-2 (Wuhan-1) nucleocapsid and

367 membrane peptides (17mers with 10 amino acid overlap spanning the full proteins) were

368 obtained from BEI Resources and were prepared by resuspending in dimethyl sulfoxide

369 (DMSO, Sigma) and used at a concentration of 1  $\mu$ g/ml.

# 370 Enzyme-linked immunosorbent assay (ELISA)

371 SARS-CoV-2-specific enzyme-linked immunosorbent assay (ELISA) was performed to

characterize the serostatus of participants, as previously described <sup>80</sup>. Two ug/ml of spike

protein was used to coat 96-well high-binding plates and incubated overnight at 4 °C. The

- plates were incubated in a blocking buffer consisting of 1% casein, 0.05% Tween 20, 1x
- Phosphate-Buffered Saline (PBS) for SARS-CoV-2 or 1x PBS, 5% skimmed milk powder,

- 376 0.05% Tween 20 for HCoVs. Plasma samples were diluted to 1:50 for SARS-CoV-2 or 1:100
- 377 for HCoVs in the respective blocking buffer. For the SARS-CoV-2 ELISA, secondary
- antibody was diluted to 1:5000 in dilution buffer and added to the plates followed by
- 379 SigmaFast O-phenylenediamine dihydrochloride (OPD) substrate. For the HCoV ELISAs,
- secondary antibody was diluted to 1:3000 in blocking buffer and added to the plates followed
- by TMB substrate (Thermofisher Scientific). Upon stopping the reaction with 1-3 M sulfuric
- acid, absorbance was measured at a wavelength of 490 nm for SARS-CoV-2 or 450 nm for
- 383 HCoVs. A cut-off for positivity was set at two standard deviations (SD) above the mean
- 384 optical density (OD) of prepandemic samples for SARS-CoV-2 ELISAs
- 385 Whole blood-based T cell assay

Blood was collected in sodium heparin tubes and processed within 4-6 hours of collection.

387 The whole blood assay sample processing used for this study was adapted from a whole

- blood intracellular cytokine detection assay designed to detect SARS-CoV-2 specific T cells
- in adults <sup>81,82</sup>. Briefly, 500 µl of blood was stimulated for 24 hours at 37°C with a combined
- 390 pool of SARS-CoV-2 peptides including S, N and M, all at  $1 \mu g/mL$  in the presence of
- costimulatory antibodies against CD28 (clone 28.2) and CD49d (clone L25) (1 μg/mL each;
- 392 BD Biosciences) and Brefeldin A (10 µg/mL, Sigma-Aldrich). Unstimulated blood was
- incubated with costimulatory antibodies, Brefeldin A and an equimolar amount of DMSO as
- a background control. After 24 hours, blood was treated with EDTA (2 mM) for 15 minutes
- followed by red blood cell lysis and white cell fixation using FACS lysing solution (BD
- Biosciences) for 10 minutes. Cells were then cryopreserved in freezing media (90% fetal
- bovine serum (FBS) and 10% DMSO) and stored at -80°C until batched analysis.
- 398 Cell staining and flow cytometry
- 399 Cell staining was performed on cryopreserved fixed cells that were thawed and washed with
- 400 1% FACS washing buffer (1% FBS in PBS). Cells were stained with the following surface
- 401 antibody markers: CD4 ECD (SFCI12T4D11, Beckman Coulter), CD8 BV510 (RPA-8,
- 402 Biolegend) and incubated at room temperature for 20 minutes. Cells were permeabilized and
- 403 stained with intracellular antibody markers CD3 BV650 (OKT3), IFN-γ AlexaFluor® 700
- 404 (B27), TNF-α BV786 (Mab11) and IL-2 APC (MQ1-17H12) (all from Biolegend). Finally,
- 405 cells were washed and fixed with Cellfix (BD Biosciences). Samples were acquired on a
- 406 multiparameter BD Fortessa flow cytometer using Diva software version 8 and analyzed
- using FlowJo v10. Results are expressed as the frequency of CD4+ or CD8+ T cells

- 408 expressing IFN- $\gamma$ , TNF- $\alpha$  or IL-2. Cytokine responses presented are background subtracted
- 409 values (from the frequency of cytokine produced by unstimulated cells).

410

# 411 QUANTIFICATION AND STATISTICAL ANALYSIS

412 Statistical analyses were performed in Prism (v9.4.1; GraphPad Software Inc, San Diego,

413 CA, USA). Non-parametric tests were used for all comparisons. The Mann-Whitney and

414 Wilcoxon signed rank tests were used for unmatched and paired samples, respectively. Chi-

square tests were used for comparisons between the proportion of responders represented as

416 pie charts. All correlations reported are non-parametric Spearman's correlations. Analysis of

417 cytokine co-expressing populations was performed using SPICE version 5.1. *P* values less

than 0.05 were considered statistically significant. Details of analyses performed for each

- 419 experiment are described in the figure legends.
- 420

#### 421 ACKNOWLEDGEMENTS

422 We thank the study participants and the parents/guardians of the children and the clinical staff 423 and personnel at Red Cross War Memorial Children's Hospital, the Drakenstein Child Health 424 Study in Paarl, Western Cape and at Groote Schuur Hospital, Cape Town for their 425 participation. We acknowledge Guarav Kwatra and Shabir Madhi for providing plasmids 426 used for the endemic ELISA proteins. BEI resources provided the following reagents NIAID, 427 NIH: Peptide Array, SARS-Related Coronavirus 2 Nucleocapsid (N) Protein, NR-52404 and 428 SARS-Related Coronavirus 2 Membrane (M) Protein, NR-52403. This work is supported by 429 the South African Medical Research Council (SA-MRC) with funds received from the South 430 African Department of Science and Innovation (DSI), (grants 96825, SHIPNCD 76756, and 431 DST/CON 0250/2012), the Poliomyelitis Research Foundation (21/65) and the Wellcome 432 Centre for Infectious Diseases Research in Africa (CIDRI-Africa), which is supported by 433 core funding from the Wellcome Trust (203135/Z/16/Z and 222754). SA-MRC to R.S.K. UK 434 NIHR GECO award (GEC111 to H.J.Z), the Bill & Melinda Gates Foundation, USA (grants 435 OPP1017641, OPP1017579 to H.J.Z). P.L.M. is supported by the South African Research 436 Chairs Initiative of the Department of Science and Innovation and National Research 437 Foundation of South Africa (NRF 9834), the SA Medical Research Council SHIP programme 438 and the Centre for the AIDS Programme of Research in South Africa (CAPRISA). C.R. is

439 supported by the EDCTP2 program of the European Union's Horizon 2020 programme 440 (TMA2017SF-1951-TB-SPEC), the Wellcome Trust (226137/Z/22/Z) and the National 441 Institutes of Health (NIH) (R21AI148027). W.A.B. is supported by the EDCTP2 program of 442 the European Union's Horizon 2020 programme (TMA2016SF-1535-CaTCH-22), the 443 Wellcome Trust (226137/Z/22/Z) and the EU-Africa Concerted Action on SARS-CoV-2 444 Virus Variant and Immunological Surveillance (COVICIS), funded through the EU's 445 Horizon Europe Research and Innovation Programme (101046041). H.J.Z is supported by the 446 SA-MRC. LZ is funded by the South African Medical Research Council (SAMRC) through 447 its Division of Research Capacity Development under the Mid-Career Scientist Programme 448 from funding received from the South African National Treasury. The content hereof is the 449 sole responsibility of the authors and do not necessarily represent the official views of the 450 SAMRC. LJ Zühlke also receives support from the National Research Foundation of South 451 Africa (NRFSA), as well as the UK Medical Research Council (MRC) and the UK 452 Department for International Development (DFID) under the MRC/DFID Concordat 453 agreement, via the African Research Leader Award (MR/S005242/1).

454

# 455 AUTHOR CONTRIBUTIONS

456 R.S.K., K.W. and W.A.B. conceived the study and designed the experiments. N.S.B.B., A.N.

457 and R.B. performed T cell assays. M.B.T., V.S. and A.W. performed SARS-CoV-2 ELISAs.

458 S.V.G. and S.R.B. performed HCoV ELISAs. N.S.B.B., T.M.G., P.L.M., C.R., W.A.B. and

459 R.S.K. analyzed the data. K.W., L.Z., and C.B. established and led the Red Cross childrens

- 460 cohort. H.J.Z. established and led the Drakenstein Child Health cohort including a COVID
- sub-study. M.B and L.W. managed the Drakenstein Child Health cohort and repository.
- 462 N.A.B.N. established and led the adult HCW cohort and M.M., S.S. and M.A. recruited
- 463 participants and managed the cohort. N.S.B.B., C.R., W.A.B. and R.S.K. wrote the paper. All
- 464 authors reviewed and edited the manuscript.

465

# 466 **DECLARATION OF INTERESTS**

467 The authors have no competing interests.

468

#### 469 FIGURE LEGENDS

#### 470 Figure 1: SARS-CoV-2-specific antibody responses in children

- 471 (A) The demographic characteristics of 71 unvaccinated children included in this study. Age,
- 472 gender, SARS-CoV-2 vaccination status, SARS-CoV-2 serology and collection date are
- 473 shown.

(B) Proportion of children exhibiting antibody responses to SARS-CoV-2 spike (S) and

- 475 nucleocapsid (N) proteins.
- 476 (C) The magnitude of SARS-CoV-2 S and N IgG antibodies (OD<sub>490nm</sub>) measured by ELISA
- in seropositive children (n=41). The dotted lines indicate the cut-off for positivity which was
- 478 calculated as the mean optical density of COVID-19 prepandemic control samples. Statistical
- analysis was performed using the Wilcoxon signed rank test; p values <0.05 were considered
- 480 statistically significant and are bolded.

481

#### 482 Figure 2: SARS-CoV-2-specific T cell responses in children

- (A) Representative flow cytometry plots of SARS-CoV-2-specific interferon- $\gamma$  (IFN- $\gamma$ ), tumor
- 484 necrosis factor- $\alpha$  (TNF- $\alpha$ ) and interleukin-2 (IL-2) cytokine production from CD4+ (left) and
- 485 CD8+ (right) T cells in response to SARS-CoV-2 peptide stimulation. NS: no stimulation,
- 486 SNM: combined peptide pool of SARS-CoV-2-spike, nucleocapsid and membrane proteins.
- (B) Frequency of SARS-CoV-2-specific CD4+ T cells producing any of the measured
- 488 cytokines (IFN- $\gamma$ , IL-2 or TNF- $\alpha$ ). Children were grouped according to SARS-CoV-2
- 489 serostatus (light blue: n=41 SARS-CoV-2 seropositive; dark blue: n=30 SARS-CoV-2
- 490 seronegative). Bars represent the median of the responders, and median values are indicated.
- 491 The pie charts represent the proportion of responders with detectable T cell response to
- 492 SARS-CoV-2 SNM peptides.
- 493 (C) Frequency of SARS-CoV-2-specific CD8+ T cells producing any of the measured
- 494 cytokines (IFN- $\gamma$ , IL-2 or TNF- $\alpha$ ). Children were grouped according to SARS-CoV-2
- 495 serostatus (light red: n=41 SARS-CoV-2 seropositive children; dark red: n=30 SARS-CoV-2
- 496 seronegative children). Statistical comparisons in (B) and (C) were performed using the
- 497 Mann-Whitney test between seropositive and seronegative children and the Chi-square test to

498 compare the percentage of responders; p values <0.05 were considered statistically significant</li>499 and are bolded.

- 500 (D) Polyfunctional profile of SARS-CoV-2-specific CD4+ and (E) CD8+ T cells in
- seropositive and seronegative unvaccinated children. The x-axis illustrates each combination
- so which is indicated with a black circle for the presence of IFN- $\gamma$ , IL-2 and TNF- $\alpha$ . The
- 503 medians and interquartile range are shown. Each response pattern (any possible combination
- 504 of IFN- $\gamma$ , IL-2 and TNF- $\alpha$  production) is color coded and summarized in the pie charts, with
- sos each pie slice representing the median contribution of each combination to the total SARS-
- 506 CoV-2 responses. The permutation test was used to compare the statistical differences
- 507 between the pie charts and the Mann Whitney Sum Test to compare response patterns
- 508 between seropositive and seronegative children; p values <0.05 were considered statistically
- significant and are bolded.

### 510 Figure 3: SARS-CoV-2 cross-reactivity to endemic beta-HCoV in children

- 511 (A) The magnitude of HCoV-HKU-1 spike IgG levels were measured by ELISA in SARS-
- 512 CoV-2 seropositive (light blue; n=41) and seronegative (dark blue; n=29) children. Plasma
- sample was insufficient for one seronegative child therefore OD for HCoV-HKU1 was not
- 514 measured for this participant. The bars represent the median values. A statistical comparison
- 515 was performed using the Mann-Whitney test between seropositive and seronegative children;
- 516 a p value <0.05 was considered statistically significant.
- 517 (B) Correlation between the frequency of SARS-CoV-2-specific CD4+ T cells and HCoV-
- 518 HKU-1-spike IgG levels in SARS-CoV-2 seronegative children (n=29). One participant had
- 519 insufficient sample available to be included in this assay.
- 520 (C) Correlation between the frequency of SARS-CoV-2-specific CD4+ T cells and HCoV-
- 521 HKU-1-spike IgG levels in SARS-CoV-2 seropositive children (n=41). Statistical
- 522 comparisons for (B) and (C) were performed using a two-tailed non-parametric Spearman
- rank tests; p values <0.05 were considered statistically significant and are bolded and
- 524 correlation coefficients values are shown.
- 525

526

# Figure 4: SARS-CoV-2-specific T cell responses in children compared to convalescent adults

- 529 (A) The demographic characteristics of 30 unvaccinated convalescent adults included in this
- study. Age, sex, SARS-CoV-2 PCR-positivity, days since PCR test and collection date are
- shown.
- 532 (B) Frequency of SARS-CoV-2-specific CD4+ T cells producing any of the measured
- 533 cytokines (IFN- $\gamma$ , TNF- $\alpha$ , or IL-2) in SARS-CoV-2 convalescent HCW (purple; n=30) and
- seropositive children (light blue; n=41). The pie charts represent the proportion of responders
- with a detectable T cell response to SARS-CoV-2 SNM combined peptide pools. Bars
- represent median of the responders.
- 537 (C) Frequency of SARS-CoV-2-specific CD8+ T cells producing any of the measured
- 538 cytokines (IFN- $\gamma$ , TNF- $\alpha$ , or IL-2) in SARS-CoV-2 convalescent HCW (dark red; n=30) and
- seropositive children (light red; n=41). The bars represent the median of the responders and
- 540 median values are indicated. Statistical comparisons were performed using the Mann-
- 541 Whitney test between seropositive children and adults and the Chi-square test was used to
- compare the percentage of responders; p values <0.05 were considered statistically significant</li>and are bolded.
- 544 (D) Correlations between SARS-CoV-2-specific CD4+ or CD8+ T cells and age in
- 545 convalescent HCW (purple and dark red; n=30) and seropositive (light blue and light red;
- 546 n=41) children. Statistical comparisons were performed using a two-tailed non-parametric
- 547 Spearman rank tests; p values <0.05 were considered statistically significant and are bolded
- 548 and correlation coefficients are shown.
- 549
- 550
- 551
- 552
- 553
- 554
- 555

### 556 **REFERENCES**

557 1. Aleebrahim-Dehkordi E, Soveyzi F, Deravi N, Rabbani Z, Saghazadeh A, Rezaei N. Human coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 in children. J 558 559 Pediatr Nurs. 2021;56:70-79. doi:10.1016/j.pedn.2020.10.020 560 2. Chou J, Thomas PG, Randolph AG. Immunology of SARS-CoV-2 infection in children. Nat Immunol. 2022;23(2):177-185. doi:10.1038/s41590-021-01123-9 561 562 3. UNICEF. COVID-19 confirmed cases and deaths, age and sex-disaggregated data. 563 Published April 2023. https://data.unicef.org/resources/covid-19-confirmed-casesand-deaths-dashboard/. Accessed April 27, 2023. 564 565 4. Kim L, Whitaker M, Kambhampati A, et al. Hospitalization Rates and Characteristics 566 of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 1–July 25, 2020. 2020;69(32):1081-1088. 567 568 https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/purpose-569 5. COVID-NET. COVID-19-Associated Hospitalization Surveillance Network, Centers 570 for Disease Control and Prevention. Published April 2023. https://gis.cdc.gov/grasp/covidnet/covid19 5.html. Accessed April 27, 2023 571 6. 572 NICD. National Institute for Communicable Disease Monthly COVID-19 in Children:; 2022. https://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-573 19/surveillance-reports/monthly-covid-19-in-children/. Accessed April 27, 2023 574 7. 575 Nair H, Brooks A, Katz M, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. The 576 Lancet. 2011;378:1917-1930. doi:10.1016/S0140 577 578 8. Bogunovic D, Merad M. Children and SARS-CoV-2. Cell Host Microbe. 2021;29(7):1040-1042. doi:10.1016/j.chom.2021.06.015 579 580 9. Williams N, Radia T, Harman K, Agrawal P, Cook J, Gupta A. COVID-19 severe 581 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and 582 adolescents: a systematic review of critically unwell children and the association with 583 underlying comorbidities. Eur J Pediatr. 2021;180(10):3251-3252. 584 doi:10.1007/s00431-021-04036-9 585 10. Tsankov BK, Allaire JM, Irvine MA, et al. Severe COVID-19 Infection and Pediatric 586 Comorbidities: A Systematic Review and Meta-Analysis. International Journal of Infectious Diseases. 2021;103:246-256. doi:10.1016/j.ijid.2020.11.163 587 588 11. Sandoval M, Nguyen DT, Vahidy FS, Graviss EA. Risk factors for severity of 589 COVID-19 in hospital patients age 18-29 years. PLoS One. 2021;16(7):1-22. doi:10.1371/journal.pone.0255544 590 12. Koch CM, Prigge AD, Anekalla KR, et al. Age-related Differences in the Nasal 591 592 Mucosal Immune Response to SARS-CoV-2. Am J Respir Cell Mol Biol. 593 2022;66(2):206-222. doi:10.1165/rcmb.2021-0292OC

594 595 596	13.	Muus C, Luecken MD, Eraslan G, et al. Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics. <i>Nat Med.</i> 2021;27(3):546-559. doi:10.1038/s41591-020-01227-z
597 598 599	14.	Schuler BA, Habermann AC, Plosa EJ, et al. Age-determined expression of priming protease TMPRSS2 and localization of SARS-CoV-2 in lung epithelium. <i>J Clin Investig</i> . 2021;131(1):1-7. doi:10.1172/JCI140766
600 601	15.	Pierce CA, Sy S, Galen B, et al. Natural mucosal barriers and COVID-19 in children. <i>JCI Insight</i> . 2021;6(9):1-10. doi:10.1172/jci.insight.148694
602 603 604	16.	Neeland MR, Bannister S, Clifford V, et al. Innate cell profiles during the acute and convalescent phase of SARS-CoV-2 infection in children. <i>Nat Commun.</i> 2021;12(1):1-5. doi:10.1038/s41467-021-21414-x
605 606	17.	Speranza E. Children primed and ready for SARS-CoV-2. <i>Nat Microbiol.</i> 2021;6(11):1337-1338. doi:10.1038/s41564-021-00984-y
607 608 609	18.	Loske J, Röhmel J, Lukassen S, et al. Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. <i>Nat Biotechnol</i> . 2022;40(3):319-324. doi:10.1038/s41587-021-01037-9
610 611 612	19.	Yoshida M, Worlock KB, Huang N, et al. Local and systemic responses to SARS-CoV-2 infection in children and adults. <i>Nature</i> . 2021;602(7896):321-327. doi:10.1038/s41586-021-04345-x
613 614 615	20.	Cotugno N, Ruggiero A, Bonfante F, et al. Virological and immunological features of SARS-CoV-2-infected children who develop neutralizing antibodies. <i>Cell Rep.</i> 2021;34(11):1-e5. doi:10.1016/j.celrep.2021.108852
616 617 618	21.	Méndez-Echevarría A, Sainz T, Falces-Romero I, et al. Long-Term Persistence of Anti-SARS-CoV-2 Antibodies in a Pediatric Population. <i>Pathogens</i> . 2021;10(6):1-7. doi:10.3390/pathogens10060700
619 620 621	22.	Dowell AC, Butler MS, Jinks E, et al. Children develop robust and sustained cross- reactive spike-specific immune responses to SARS-CoV-2 infection. <i>Nat Immunol</i> . 2022;23(1):40-49. doi:10.1038/s41590-021-01089-8
622 623 624	23.	Cohen CA, Li APY, Hachim A, et al. SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection. <i>Nat Commun</i> . 2021;12(1):1-14. doi:10.1038/s41467-021-24938-4
625 626 627	24.	Humbert M, Olofsson A, Wullimann D, et al. Functional SARS-CoV-2 cross-reactive CD4 + T cells established in early childhood decline with age. <i>Proc Natl Acad Sci</i> . 2023;120(12):1-12. doi:10.1073/pnas.2220320120
628 629 630	25.	Woudenberg T, Pelleau S, Anna F, et al. Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France. <i>EBioMedicine</i> . 2021;70:1-10. doi:10.1016/j.ebiom.2021.103495
631 632	26.	Nickbakhsh S, Ho A, Marques DFP, McMenamin J, Gunson RN, Murcia PR. Epidemiology of Seasonal Coronaviruses: Establishing the Context for the Emergence

633 634		of Coronavirus Disease 2019. <i>J Infect Dis</i> . 2020;222(1):17-25. doi:10.1093/infdis/jiaa185
635 636	27.	Zimmermann C, Curtis N. Coronavirus Infections in Children Including COVID-19. <i>Pediatr Infect Dis J</i> . 2020;39(5):355-368. doi:10.1097/INF.00000000002660
637 638	28.	Fehr R A PS. Coronaviruses: An Overview of Their Replication and Pathogenesis. <i>Methods Mol Biol</i> . 2015;1282:1-23. doi:10.1007/978-1-4939-2438-7_1.
639 640 641	29.	Park S, Lee Y, Michelow IC, Choe YJ. Global Seasonality of Human Coronaviruses: A Systematic Review. <i>Open Forum Infect Dis.</i> 2020;7(11):1-7. doi:10.1093/ofid/ofaa443
642 643 644	30.	Audi A, Allbrahim M, Kaddoura M, Hijazi G, Yassine HM, Zaraket H. Seasonality of Respiratory Viral Infections: Will COVID-19 Follow Suit? <i>Front Public Health</i> . 2020;8:1-8. doi:10.3389/fpubh.2020.567184
645 646	31.	Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. <i>Cell</i> . 2021;184(4):861-880. doi:10.1016/j.cell.2021.01.007
647 648 649	32.	Garrido C, Hurst JH, Lorang CG, et al. Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents. <i>JCI Insight</i> . 2021;6(17):1-13. doi:10.1172/jci.insight.150909
650 651 652	33.	Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. <i>Science</i> . 2021;371(6529):1-23. doi:10.1126/science.abf4063
653 654 655	34.	Guo L, Wang G, Wang Y, et al. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study. <i>Lancet Microbe</i> . 2022;3(5):e348-e356. doi:10.1016/S2666-5247(22)00036-2
656 657 658	35.	Zuo J, Dowell AC, Pearce H, et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. <i>Nat Immunol.</i> 2021;22(5):620-626. doi:10.1038/s41590-021-00902-8
659 660 661	36.	Pierce CA, Preston-Hurlburt P, Dai Y, et al. Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. <i>Sci Transl Med.</i> 2020;12(564):1-11. doi:10.1126/scitranslmed.abe8120
662 663 664	37.	Kaaijk P, Pimentel VO, Emmelot ME, et al. Children and Adults With Mild COVID- 19: Dynamics of the Memory T Cell Response up to 10 Months. <i>Front Immunol</i> . 2022;13:1-15. doi:10.3389/fimmu.2022.817876
665 666 667	38.	Tosif S, Neeland MR, Sutton P, et al. Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19. <i>Nat Commun.</i> 2020;11(1):1-8. doi:10.1038/s41467-020-19545-8
668 669 670	39.	Tegally H, Wilkinson E, Giovanetti M, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. <i>Nature</i> . 2021;592(7854):438-443. doi:10.1038/s41586-021-03402-9

671 672	40.	Moss P. The T cell immune response against SARS-CoV-2. <i>Nat Immunol</i> . 2022;23(2):186-193. doi:10.1038/s41590-021-01122-w
673 674 675	41.	Tsang HW, Chua GT, To KKW, et al. Assessment of SARS-CoV-2 Immunity in Convalescent Children and Adolescents. <i>Front Immunol</i> . 2021;12:1-10. doi:10.3389/fimmu.2021.797919
676 677 678	42.	Paul K, Sibbertsen F, Weiskopf D, et al. Specific CD4+ T Cell Responses to Ancestral SARS-CoV-2 in Children Increase With Age and Show Cross-Reactivity to Beta Variant. <i>Front Immunol</i> . 2022;13:1-12. doi:10.3389/fimmu.2022.867577
679 680 681	43.	Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. <i>Cell</i> . 2020;181(7):1489-1501. doi:10.1016/j.cell.2020.05.015
682 683 684	44.	Mateus J, Grifoni A, Tarke A, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. <i>Science</i> . 2020;370(6512):89-94. doi:10.1126/science.abd3871
685 686 687	45.	Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. <i>Nature</i> . 2020;584(7821):457-462. doi:10.1038/s41586-020-2550-z
688 689 690	46.	Swadling L, Diniz MO, Schmidt NM, et al. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. <i>Nature</i> . 2021;601(7891):110-117. doi:10.1038/s41586-021-04186-8
691 692 693	47.	Tan HX, Lee WS, Wragg KM, et al. Adaptive immunity to human coronaviruses is widespread but low in magnitude. <i>Clin Transl Immunology</i> . 2021;10(3):1-15. doi:10.1002/cti2.1264
694 695 696 697	48.	Singh V, Obregon-Perko V, Lapp SA, et al. Limited induction of SARS-CoV-2– specific T cell responses in children with multisystem inflammatory syndrome compared with COVID-19. <i>JCI Insight</i> . 2022;7(4):1-13. doi:10.1172/jci.insight.155145
698 699 700	49.	Shah MM, Winn A, Dahl RM, Kniss KL, Silk BJ, Killerby ME. Seasonality of Common Human Coronaviruses, United States, 2014-2021. <i>Emerg Infect Dis</i> . 2022;28(10):1970-1976. doi:10.3201/eid2810.220396
701 702 703	50.	de Vries RD. SARS-CoV-2-specific T-cells in unexposed humans: presence of cross- reactive memory cells does not equal protective immunity. <i>Signal Transduct Target</i> <i>Ther</i> . 2020;5(1):1-2. doi:10.1038/s41392-020-00338-w
704 705 706	51.	Zar HJ, Nicol MP, MacGinty R, et al. Antibodies to seasonal coronaviruses rarely cross-react with SARS-CoV-2: findings from an African birth cohort. <i>Pediatr Infect Dis J</i> . 2021;40(12):e516-e519. doi:10.1097/INF.00000000003325
707 708 709	52.	Da Silva Antunes R, Pallikkuth S, Williams E, et al. Differential T-Cell Reactivity to Endemic Coronaviruses and SARS-CoV-2 in Community and Health Care Workers. <i>J Infect Dis</i> . 2021;224(1):70-80. doi:10.1093/infdis/jiab176

710 711 712	53.	Woldemeskel BA, Kwaa AK, Garliss CC, Laeyendecker O, Ray SC, Blankson JN. Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2. <i>J</i> <i>Clin Investig</i> . 2020;130(12):6631-6638. doi:10.1172/JCI143120
713 714 715	54.	Loyal L, Braun J, Henze L, et al. Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. <i>Science</i> . 2021;374(6564):1-11. doi:10.1126/science.abh1823
716 717 718	55.	Nelde A, Bilich T, Heitmann JS, et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. <i>Nat Immunol.</i> 2021;22(1):74-85. doi:10.1038/s41590-020-00808-x
719 720 721	56.	Kundu R, Narean JS, Wang L, et al. Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. <i>Nat Commun</i> . 2022;13(1):1-8. doi:10.1038/s41467-021-27674-x
722 723 724 725	57.	Yu ED, Narowski TM, Wang E, et al. Immunological memory to common cold coronaviruses assessed longitudinally over a three-year period pre-COVID19 pandemic. <i>Cell Host Microbe</i> . 2022;30(9):1269-1278. doi:10.1016/j.chom.2022.07.012
726 727 728	58.	Saletti G, Gerlach T, Jansen JM, et al. Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63. <i>Sci Rep</i> . 2020;10(1):1-10. doi:10.1038/s41598-020-78506-9
729 730 731	59.	Niessl J, Sekine T, Lange J, et al. Identification of resident memory CD8 + T cells with functional specificity for SARS-CoV-2 in unexposed oropharyngeal lymphoid tissue. <i>Sci Immunol</i> . 2021;6(64):1-11. doi: 10.1126/sciimmunol.abk0894
732 733 734	60.	Sagar M, Reifler K, Rossi M, et al. Recent endemic coronavirus infection is associated with less-severe COVID-19. <i>J Clin Investig</i> . 2021;131(1):1-5. doi:10.1172/JCI143380
735 736 737	61.	Da Silva Antunes R, Pallikkuth S, Williams E, et al. Differential T-Cell Reactivity to Endemic Coronaviruses and SARS-CoV-2 in Community and Health Care Workers. <i>J Infect Dis</i> . 2021;224(1):70-80. doi:10.1093/infdis/jiab176
738 739 740 741	62.	Dowell AC, Ireland G, Zuo J, Moss P, Ladhani S. Association of Spike-Specific T Cells with Relative Protection from Subsequent SARS-CoV-2 Omicron Infection in Young Children. <i>JAMA Pediatr</i> . 2022;177(1):96-97. doi:10.1001/jamapediatrics.2022.3868
742 743 744	63.	Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: Implications for vaccine design. <i>Nat Rev Immunol</i> . 2008;8(4):247-258. doi:10.1038/nri2274
745 746 747	64.	Snyder LD, Chan C, Kwon D, et al. Polyfunctional T-cell signatures to predict protection from cytomegalovirus after lung transplantation. <i>Am J Respir Crit Care Med.</i> 2016;193(1):78-85. doi:10.1164/rccm.201504-0733OC

748 749 750	65.	Ciuffreda D, Comte D, Cavassini M, et al. Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication. <i>Eur J Immunol</i> . 2008;38(10):2665-2677. doi:10.1002/eji.200838336
751 752 753	66.	Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. <i>Blood</i> . 2006;107(12):4781-4789. doi:10.1182/blood-2005-12-4818
754 755 756	67.	Altmann DM, Boyton RJ. SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. <i>Sci Immunol</i> . 2020;5(49):1-5. doi:10.1126/sciimmunol.abd6160
757 758 759	68.	Bertoletti A, Le Bert N, Tan AT. SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic. <i>Immunity</i> . 2022;55(10):1764-1778. doi:10.1016/j.immuni.2022.08.008
760 761 762 763	69.	Spear TT, Evavold BD, Baker BM, Nishimura MI. Understanding TCR affinity, antigen specificity, and cross-reactivity to improve TCR gene-modified T cells for cancer immunotherapy. <i>Cancer Immunol, Immunother</i> . 2019;68(11):1881-1889. doi:10.1007/s00262-019-02401-0
764 765 766	70.	Stone JD, Chervin AS, Kranz DM. T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. <i>Immunology</i> . 2009;126(2):165-176. doi:10.1111/j.1365-2567.2008.03015.x
767 768 769	71.	Tan MP, Gerry AB, Brewer JE, et al. T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells. <i>Clin Exp Immunol</i> . 2015;180(2):255-270. doi:10.1111/cei.12570
770 771	72.	Jarjour NN, Masopust D, Jameson SC. T Cell Memory: Understanding COVID-19. <i>Immunity</i> . 2021;54(1):14-18. doi:10.1016/j.immuni.2020.12.009
772 773 774	73.	Rydyznski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. <i>Cell</i> . 2020;183(4):996-1012.e19. doi:10.1016/j.cell.2020.09.038
775 776 777	74.	Mahnke YD, Brodie TM, Sallusto F, Roederer M, Lugli E. The who's who of T-cell differentiation: Human memory T-cell subsets. <i>Eur J Immunol</i> . 2013;43(11):2797-2809. doi:10.1002/eji.201343751
778 779 780 781	75.	Ssemaganda A, Nguyen HM, Nuhu F, et al. Expansion of cytotoxic tissue-resident CD8+ T cells and CCR6+CD161+ CD4+ T cells in the nasal mucosa following mRNA COVID-19 vaccination. <i>Nat Commun.</i> 2022;13(1):1-9. doi:10.1038/s41467-022-30913-4
782 783 784 785	76.	Lim JME, Tan AT, Bert N Le, Hang SK, Low JGH, Bertoletti A. SARS-CoV-2 breakthrough infection in vaccinees induces virus-specific nasal-resident CD8+ and CD4+ T cells of broad specificity. <i>J Exp Med.</i> 2022;219(10):1-10. doi:10.1084/jem.20220780
786 787	77.	Weatherhead JE, Clark E, Vogel TP, Atmar RL, Kulkarni PA. Inflammatory syndromes associated with SARS-cov-2 infection: Dysregulation of the immune

788 789		response across the age spectrum. <i>J Clin Investig</i> . 2020;130(12):6194-6197. doi:10.1172/JCI145301
790 791 792	78.	Zar HJ, Barnett W, Myer L, Stein DJ, Nicol MP. Investigating the early-life determinants of illness in Africa: the Drakenstein Child Health Study. <i>Thorax</i> . 2015;70(6):592-594. doi:10.1136/thoraxjnl-2014-206242
793 794 795	79.	Zar HJ, MacGinty R, Workman L, et al. Natural and hybrid immunity following four COVID-19 waves: A prospective cohort study of mothers in South Africa. <i>EClinicalMedicine</i> . 2022;53:1-12. doi:10.1016/j.eclinm.2022.101655
796 797 798	80.	Makatsa MS, Tincho MB, Wendoh JM, et al. SARS-CoV-2 Antigens Expressed in Plants Detect Antibody Responses in COVID-19 Patients. <i>Front Plant Sci.</i> 2021;12:1- 13. doi:10.3389/fpls.2021.589940
799 800 801	81.	Mutavhatsindi H, Riou C. Protocol to quantify and phenotype SARS-CoV-2-specific T cell response using a rapid flow-cytometry-based whole blood assay. <i>STAR Protoc</i> . 2022;3(4):1-15. doi:10.1016/j.xpro.2022.101771
802 803 804	82.	Riou C, Schäfer G, du Bruyn E, et al. Rapid, simplified whole blood-based multiparameter assay to quantify and phenotype SARS-CoV-2-specific T-cells. <i>Eur Respir</i> . 2022;59(1):1-13. doi:10.1183/13993003.00285-2021
805		
806		

807 Click or tap here to enter text.

Α	Children	
N	71	
Age (median, IQR)	7 (2.8 - 9)	
Gender (n, % female)	24 (34%)	
SARS-CoV-2 vaccination (n, %)	0 (0%)	
SARS-CoV-2 seropositive (n, %)	41 (58%)	
Sample collection date	1 February 2021 – 20 May 2021	

B All children (n=71)









	Convalescent adults
Ν	30
Age (median, IQR)	37.5 (32.3 - 45.3)
Gender (n, % female)	22 (73%)
SARS-CoV-2 PCR positivity (n, %)	30 (100%)
Days since PCR+ (median, IQR)	224 (189 - 239)
Sample collection date	22 January 2021 - 23 February 2021









A